TALVEY® is administered via subcutaneous injection by a healthcare provider Q2W or QW following the step-up dosing schedule1

Talvey dosing calendar for Q2W dosing. Step up dose for day one of treatment 0.01 mg/kg. Day 4 step up dosing 0.06 mg/kg.
Talvey dosing calendar for Q2W dosing. Step up dose for day one of treatment 0.01 mg/kg. Day 4 step up dosing 0.06 mg/kg.

TALVEY® is given until disease progression or unacceptable toxicity.

You make the move with step-up dosing flexibility:

Step-up doses may be administered between 2 to 4 days after the previous dose and maybe given up to 7 days after the previous dose to allow for resolution of adverse reactions. The full step-up dosing schedule can be completed in 7 days for Q2W and 5 days for QW.

Dosing considerations

Circle with downward arrows

Initiate TALVEY® treatment with step-up dosing to reduce the risk of CRS.

Hand with syringe

Dose delays may be required to manage toxicities.

Preparation and administration considerations

Location balloon with plus sign icon

Due to the risk of CRS and neurologic toxicity, including ICANS, patients should be hospitalized for 48 hours after administration of all doses within the TALVEY® step-up dosing schedule.

Location balloon with plus sign icon

Rapid subcutaneous injection: TALVEY® does not require the wait time associated with infusions.1,2


Ready-to-use solution without need for dilution.


Subcutaneous injection into abdomen (preferred) or thigh.


Use aseptic technique to prepare and administer TALVEY®.


Do not combine TALVEY® vials of different concentrations to achieve treatment dose.


Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Check that the TALVEY® solution for injection is colorless to light yellow. Do not use if the solution is discolored, cloudy, or if foreign particles are present.

Personalized weight-based dosing

Please refer to Tables 9-12 in the full Prescribing Information to determine total dose, injection volume, and number of vials required.

Pretreatment medications


1 to 3 hours before each step-up dose

Administer the following pretreatment medications before each dose in the step-up dosing schedule to reduce the risk of CRS

  • Corticosteroid (oral or intravenous dexamethasone 16 mg or equivalent)
  • Antihistamines (oral or intravenous diphenhydramine 50 mg or equivalent)
  • Antipyretics (oral or intravenous acetaminophen 650 mg to 1,000 mg or equivalent)

Subsequent doses

Administration of pretreatment medications may be required for subsequent doses for patients who repeat doses within the TALVEY® step-up dosing schedule due to dose delays or for patients who experienced CRS.

Dose modifications

View dose modification recommendations for the management of:

Other adverse reactions include oral toxicity and weight loss, infections, cytopenias, skin reactions, and other non-hematologic adverse reactions.


Based on actual body weight.

CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; QW, once weekly; Q2W, every 2 weeks; SUD, step-up dosing.

  1. TALVEY® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  2. Kim H, Park H, Lee SJ. Effective method for drug injection into subcutaneous tissue. Sci Rep. 2017;7(1):9613.